So Far, So Good for Gilead's Blockbuster
Some good news came out of Gilead this morning, as the company's drug Sofosbuvir was deemed safe enough to continue with a critical phase 3 trial. This drug is a vital part of Gilead's focus on hepatitis C, but this class of drugs has had some safety questions in the past. In the following video, Fool health-care analyst David Williamson tells investors what the key things to watch will be, now that Gilead has gotten the go-ahead to move into this major phase 3 trial.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article So Far, So Good for Gilead's Blockbuster originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.